XNASTMDX
Market cap2.32bUSD
Jan 10, Last price
68.99USD
1D
-4.91%
1Q
-48.97%
IPO
178.19%
Name
Transmedics Group Inc
Chart & Performance
P/E
—
P/S
9.58
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
11.06%
Rev. gr., 5y
79.36%
Revenues
242m
+158.53%
Net income
-25m
L-30.92%
CFO
-13m
L-71.57%
Earnings
Feb 24, 2025
Profile
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 241,623 158.53% | 93,459 208.83% | ||||||
Cost of revenue | 243,138 | 124,896 | ||||||
Unusual Expense (Income) | ||||||||
NOPBT | (1,515) | (31,437) | ||||||
NOPBT Margin | ||||||||
Operating Taxes | (1,643) | 66 | ||||||
Tax Rate | ||||||||
NOPAT | 128 | (31,503) | ||||||
Net income | (25,028) -30.92% | (36,231) -18.06% | ||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 955 | 145,977 | ||||||
BB yield | -0.04% | -8.00% | ||||||
| Debt | ||||||||
Debt current | 4,070 | 1,444 | ||||||
Long-term debt | 523,653 | 74,970 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 132,911 | (125,268) | ||||||
| Cash flow | ||||||||
Cash from operating activities | (13,028) | (45,817) | ||||||
CAPEX | (151,847) | (11,907) | ||||||
Cash from investing activities | (193,953) | 54,513 | ||||||
Cash from financing activities | 400,418 | 167,927 | ||||||
FCF | (192,089) | (66,048) | ||||||
| Balance | ||||||||
Cash | 394,812 | 201,182 | ||||||
Long term investments | 500 | |||||||
Excess cash | 382,731 | 197,009 | ||||||
Stockholders' equity | 137,202 | 187,375 | ||||||
Invested Capital | 517,981 | 67,555 | ||||||
ROIC | 0.04% | |||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 32,517 | 29,557 | ||||||
Price | 78.93 27.88% | 61.72 222.13% | ||||||
Market cap | 2,566,596 40.69% | 1,824,235 244.76% | ||||||
EV | 2,699,507 | 1,698,967 | ||||||
EBITDA | 6,662 | (27,959) | ||||||
EV/EBITDA | 405.21 | |||||||
Interest | 10,791 | 3,726 | ||||||
Interest/NOPBT | ||||||||